<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39354444</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2431</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>BMC pediatrics</Title><ISOAbbreviation>BMC Pediatr</ISOAbbreviation></Journal><ArticleTitle>Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients.</ArticleTitle><Pagination><StartPage>625</StartPage><MedlinePgn>625</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">625</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12887-024-05071-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">IL-6 polymorphisms were associated to viral infection outcomes through affection of IL-6 production and it is an early indicator of tissue injury and systemic inflammatory response. The study aimed to determine whether genetic IL-6 polymorphisms, serum interleukin-6 level and inflammatory markers (Presepsin, CXCL-10, C3, and C4) are associated with the prediction of disease severity in pediatric COVID-19 patients and its possible use as a prognostic tool in pediatric patients admitted to hospital.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study was conducted on 150 children with COVID-19. Patients were divided according to the severity of infection into four groups: group I (mild) 67 cases; group II (moderate) 53 cases, group III (severe) 17 cases and group IV (critical) 14 cases. Serum Interleukin 6, CXCL-10, Presepsin, renal and liver functions, electrolytes, C3, C4, ferritin, and D dimer serum levels were assessed in all patients. The Kruskal Wallis test used to compare parametric quantitative data between studied groups and Mann Whitney test for each pair of groups. Non-parametric quantitative data was compared between studied groups using a one-way ANOVA test and post-hoc Bonferroni analysis for each pair of groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Group I: 35 males and 32 females with a median age of 16 months. Group II: 17 males and 35 females with a median age of 13 months. Group III: 6 males and 11 females with a median age of 12 months and group IV: 3 males and 11 females with a median age of 12 months. There was no statistical difference between the studied groups regarding gender and age. Serum levels of IL- 6, serum ferritin; D-dimer, Presepsin and CXCL 10 were significantly higher in both severe and critical groups than the other 2 groups (mild and moderate). ROC curve analysis showed that interleukin-6 and Presepsin were good markers for prediction of severity of COVID-19 among the diseased children. For severe cases, the sensitivity of interleukin-6 was 76.47% and specificity was 92.31%. For critical cases, the sensitivity of interleukin-6 was 71.43% and specificity was 82.35%. The sensitivity of Presepsin was 76.47% and specificity was 88.46% in severe cases. For critical cases, the sensitivity of Presepsin was 78.57% and specificity of 91.2%. There was significant difference in IL-6 572 allelic among moderate cases with the most frequent 42.3% for genotype (GC) and allelic among severe cases with the most frequent 47.1% for genotype (GC). Significant difference in IL-6 174 allelic among critical cases with the most frequent 78.6% for genotype (CC).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Children whom expressed GC genotypes of IL6 (-572G &gt; C) polymorphism are at a considerably higher risk of developing a severe disease. This risk is significantly larger in the severe group of children than in children in critical condition who have GC genotypes of IL6 (-174 G &gt; C) polymorphism. While IL6 (-597G &gt; A) polymorphism has no role in COVID 19 severity in children.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>AbdelAziz</LastName><ForeName>Reem A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd-Allah</LastName><ForeName>Samir Tamer</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moness</LastName><ForeName>Hend M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Clinical Pathology Department, Faculty of Medicine, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Ahmed M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Zamzam Hassan</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Minia University, Minia, Egypt. Zamzam.Hassan@minia.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pediatr</MedlineTA><NlmUniqueID>100967804</NlmUniqueID><ISSNLinking>1471-2431</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">IL-6 polymorphism</Keyword><Keyword MajorTopicYN="N">Prediction</Keyword><Keyword MajorTopicYN="N">Prognostic value</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354444</ArticleId><ArticleId IdType="pmc">PMC11443869</ArticleId><ArticleId IdType="doi">10.1186/s12887-024-05071-9</ArticleId><ArticleId IdType="pii">10.1186/s12887-024-05071-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu F, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Smetana K Jr, Rosel D, Br Ábek J. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality. In Vivo. 2020;34(5):3027–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652447</ArticleId><ArticleId IdType="pubmed">32871847</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz VJ, et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598743</ArticleId><ArticleId IdType="pubmed">33130000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulhaq ZS, Soraya GV. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia. Med Clin (Barc). 2020;155(12):548–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832797</ArticleId><ArticleId IdType="pubmed">33521302</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijotas-Reig J, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;19(7):102569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252146</ArticleId><ArticleId IdType="pubmed">32376394</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194601</ArticleId><ArticleId IdType="pubmed">32344011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobias H, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv. 2020:2020.04.01.20047381.</Citation></Reference><Reference><Citation>Zeng F, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233226</ArticleId><ArticleId IdType="pubmed">32425643</ArticleId></ArticleIdList></Reference><Reference><Citation>Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2020;8:607647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042162</ArticleId><ArticleId IdType="pubmed">33859967</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez-Salinas L, et al. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019;10:1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524401</ArticleId><ArticleId IdType="pubmed">31134045</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukim N, et al. Cytokine gene polymorphism in human disease: on-line databases, Supplement 2. Genes Immun. 2002;3(6):313–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, et al. The association between three IL-6 polymorphisms and HBV-related liver diseases: a meta-analysis. Int J Clin Exp Med. 2015;8(10):17036–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694194</ArticleId><ArticleId IdType="pubmed">26770294</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitkauskaite A, et al. IL-6 597A/G (rs1800797) and 174G/C (rs1800795) Gene Polymorphisms in the Development of Cervical Cancer in Lithuanian Women. Medicina (Kaunas). 2021;57(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8538235</ArticleId><ArticleId IdType="pubmed">34684062</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari Nia M, Rokni M, Mirinejad S, Kargar M, Rahdar S, Sargazi S, Sarhadi M, Saravani R. Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: a case-control study and in silico analyses. J Med Virol. 2022;94:1502–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015227</ArticleId><ArticleId IdType="pubmed">34821383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali HN, Niranji SS, Al-Jaf SMA. Association of tumor necrosis factor alpha– 308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi kurdish population. J Clin Lab Anal. 2022;36:e24400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9102518</ArticleId><ArticleId IdType="pubmed">35373411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabrey FL, et al. Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019. Crit Care Explor. 2021;3(12):e0591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8663850</ArticleId><ArticleId IdType="pubmed">34909698</ArticleId></ArticleIdList></Reference><Reference><Citation>AL-Khikani FH, Abdulridha Alkhafaji Z. Impact of IL-35 and presepsin on immunological, hematological, and biochemical parameters in COVID-19 patients. J Infect Epidemiol Microbiol. 2023;9(1):35–42.</Citation></Reference><Reference><Citation>Al-Hussainy AD, AL-Khikani FH, Hussein AZ, Alshamary RS. Correlation between severe acute respiratory syndrome Coronavirus-2 and cytomegalovirus. Medical Journal of Dr DY Patil University. 2022;15(Suppl 2):S286–90.</Citation></Reference><Reference><Citation>Lorè NI, et al. CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Mol Med. 2021;27(1):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521494</ArticleId><ArticleId IdType="pubmed">34663207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran R, et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PLoS ONE. 2021;16(7):e0254367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270414</ArticleId><ArticleId IdType="pubmed">34242356</ArticleId></ArticleIdList></Reference><Reference><Citation>Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">24499275</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle NS, et al. Complement System Part II: Role in Immunity. Front Immunol. 2015;6:257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443744</ArticleId><ArticleId IdType="pubmed">26074922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020;181(4):914–921.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179501</ArticleId><ArticleId IdType="pubmed">32330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Torretta S, et al. Incidental lowering of otitis-media complaints in otitis-prone children during COVID-19 pandemic: not all evil comes to hurt. Eur J Pediatr. 2021;180(2):649–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370867</ArticleId><ArticleId IdType="pubmed">32691131</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://iris.who.int/handle/10665/332196.</Citation></Reference><Reference><Citation>Falahi S, et al. Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population. Cytokine. 2022;154:155889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015956</ArticleId><ArticleId IdType="pubmed">35461173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J, Li F. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) Is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2020;71:1937–42. 10.1093/cid/ciaa449.[PubMed][CrossRef][GoogleScholar].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Alseoudy MM, et al. Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study. Clin Immunol. 2022;235:108929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767970</ArticleId><ArticleId IdType="pubmed">35063671</ArticleId></ArticleIdList></Reference><Reference><Citation>Maione F, et al. Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomed Pharmacother. 2021;142:111980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8318692</ArticleId><ArticleId IdType="pubmed">34364043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerget F, Kerget B. Frequency of Interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) Polymorphisms in COVID-19 Patients in Turkey Who Develop Macrophage Activation Syndrome. Jpn J Infect Dis. 2021;74(6):543–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33952771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganda IJ, Putri TK, Rauf S, Laompo A, Pelupessy NM, Lawang SA, et al. IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection’s mortality in children. PLOS ONE. 2023;18(10):e0293639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10610523</ArticleId><ArticleId IdType="pubmed">37889917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail S, Essawi M. Genetic polymorphism studies in humans. Middle East J Med Genet. 2012;1(2):57–63.</Citation></Reference><Reference><Citation>Shalaby HM, et al. Assessment of interleukin-6 role in detecting coronavirus disease 2019 severity, mortality, and its control: A cohort study. 2023;72(2):183–190.</Citation></Reference><Reference><Citation>Zhang J, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med. 2020;18(1):406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594951</ArticleId><ArticleId IdType="pubmed">33121497</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Verma S, Khan FH, Siddiqi Z, Raza ST, Abbas M, Mahdi F. Genetic polymorphisms of IL6 gene -174G &gt; C and -597G &gt; A are associated with the risk of COVID-19 severity. Int J Immunogenet. 2023;50(1):5–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878250</ArticleId><ArticleId IdType="pubmed">36323530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharadwaj, N.K.a.S., Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans. 2020. 10.1080/07391102.2020.1776640.</Citation><ArticleIdList><ArticleId IdType="pubmed">32490733</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal HH, et al. Presepsin as a Novel Biomarker in predicting In-hospital Mortality in Patients With COVID-19 Pneumonia. Int J Infect Dis. 2022;118:155–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893933</ArticleId><ArticleId IdType="pubmed">35248717</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldarale F, et al. Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. Front Immunol. 2021;12:654587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033149</ArticleId><ArticleId IdType="pubmed">33841438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukada A, Kitagawa Y, Matsuoka M, et al. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J Med Virol. 2021;93(1):99–101. 10.1002/jmv.26164. PMID: 32530491; PMCID: PMC7307131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307131</ArticleId><ArticleId IdType="pubmed">32530491</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaninotto M, et al. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175898</ArticleId><ArticleId IdType="pubmed">32333860</ArticleId></ArticleIdList></Reference><Reference><Citation>M Farag S, et al. Presepsin as a predictive indicator of severity in Coronavirus disease-2019 (COVID-19). Novel Res Microbiol J. 2021;5(4):1325–37.</Citation></Reference><Reference><Citation>Çağlar FNT, et al. Serum Presepsin Levels among Patients with COVID-19. 2022;13(1):17–22.</Citation></Reference><Reference><Citation>Zinellu A, Mangoni AA. Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. 2021;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8215447</ArticleId><ArticleId IdType="pubmed">34163491</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiesteban-Lores LE, et al. A double edged-sword - The Complement System during SARS-CoV-2 infection. Life Sci. 2021;272: 119245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889033</ArticleId><ArticleId IdType="pubmed">33609539</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano AM, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187144</ArticleId><ArticleId IdType="pubmed">32327719</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, et al. Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. Int J Gen Med. 2022;15:849–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801723</ArticleId><ArticleId IdType="pubmed">35115811</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7815913</ArticleId><ArticleId IdType="pubmed">33469072</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng F, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021;156(7):324–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016043</ArticleId><ArticleId IdType="pubmed">33824908</ArticleId></ArticleIdList></Reference><Reference><Citation>VanWagner LB, Green RM. Elevated serum ferritin. JAMA. 2014;312(7):743–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4424930</ArticleId><ArticleId IdType="pubmed">25138336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA. 2020;323(20):2085–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160748</ArticleId><ArticleId IdType="pubmed">32293646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194022</ArticleId><ArticleId IdType="pubmed">32017661</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325(11):1074–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905703</ArticleId><ArticleId IdType="pubmed">33625505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>